bezafibrate has been researched along with Liver Steatosis in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ackerman, Z; Amir, G; Grozovski, M; Oron-Herman, M; Rosenthal, T; Sela, BA | 1 |
| Ackerman, Z; Ben-Ari, Z; Chepurko, Y; Cohen, M; Grossman, E; Hochhauser, E; Leibowitz, A; Schmilovitz-Weiss, H; Yitzhaki, S | 1 |
| Aguila, MB; Bargut, TC; de Carvalho, SN; Magliano, DC; Mandarim-de-Lacerda, CA; Souza-Mello, V | 1 |
| Chen, R; Cheng, J; Jones, DM; Lyn, RK; Nasheri, N; O'Hara, S; Pezacki, JP; Rouleau, Y; Russell, RS; Singaravelu, R; Srinivasan, P; Tyrrell, DL | 1 |
| Hoshina, M; Karahashi, M; Kawashima, Y; Kudo, N; Mitsumoto, A; Sakamoto, T; Yamazaki, T | 1 |
| Ackerman, Z; Grozovski, M; Oron-Herman, M; Sela, BA; Skarzinski, G | 1 |
| Aichler, M; Brachthäuser, L; Feuchtinger, A; Franko, A; Fuchs, H; Häring, HU; Hrabě de Angelis, M; Kovarova, M; Neff, F; Neschen, S; Peter, A; Rathkolb, B; Rozman, J; Wolf, E | 1 |
| Enjoji, M; Fujino, T; Harada, N; Higuchi, N; Kato, M; Kohjima, M; Kotoh, K; Machida, K; Maehara, Y; Matsunaga, K; Nakamuta, M; Nakashima, M; Nishinakagawa, T; Taketomi, A; Yada, M; Yada, R; Yasutake, K; Yoshimoto, T | 1 |
| Aburada, M; Hokao, R; Iizuka, S; Makihara, H; Sasaki, Y; Shimada, T; Suzuki, W; Teraoka, R; Tsuneyama, K | 1 |
| Katsuya, T; Kiomy Osako, M; Koriyama, H; Kyutoku, M; Minobe, N; Miyake, T; Morishita, R; Moritani, T; Nakagami, F; Nakagami, H; Shimamura, M; Shimizu, H; Shimosato, T | 1 |
| Hirata, D; Isoda, N; Kamata, Y; Kamimura, T; Kanai, N; Masuyama, J; Minota, S; Yoshio, T | 1 |
| Ackerman, Z; Grozovski, M; Link, G; Oron-Herman, M; Pappo, O; Rosenthal, T; Sela, BA | 2 |
| Aishima, S; Enjoji, M; Kotoh, K; Maehara, Y; Morizono, S; Nakamuta, M; Nawata, H; Shimada, M; Soejima, Y; Takasugi, S; Taketomi, A; Uchiyama, H; Yoshimitsu, K; Yoshizumi, T | 1 |
| Ahmed, MH; Osman, KA | 1 |
| Inada, Y; Kuroda, J; Maruyama, K; Nagasawa, T; Nakano, S; Shibata, N; Takahashi, T; Tamura, T; Yamazaki, Y | 1 |
| Perkins, JD | 1 |
| Enzan, H; Ogawa, Y; Onishi, S; Saibara, T; Yoshida, S | 1 |
| Hamada, N; Inomata, T; Kariya, S; Murata, Y; Nishioka, A; Ogawa, Y; Saibara, T; Terashima, M; Yoshida, S | 1 |
| Akisawa, N; Iwasaki, S; Maeda, T; Nemoto, Y; Ogawa, Y; Onishi, S; Ono, M; Saibara, T; Xu, N; Zhang, T | 1 |
2 trial(s) available for bezafibrate and Liver Steatosis
| Article | Year |
|---|---|
Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; ATP Binding Cassette Transporter, Subfamily B; Bezafibrate; Cholestasis; Drainage; Fatty Liver; Female; gamma-Glutamyltransferase; Humans; Hypolipidemic Agents; Jaundice, Obstructive; Liver Cirrhosis, Biliary; Male; Middle Aged; Phospholipids; Polymerase Chain Reaction; PPAR alpha | 2010 |
Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation.
Topics: Adult; Bezafibrate; Biopsy; Dietary Proteins; Exercise; Fatty Liver; Female; Humans; Hypolipidemic Agents; Liver Transplantation; Living Donors; Male; Middle Aged; Preoperative Care; Severity of Illness Index; Tissue and Organ Procurement | 2005 |
18 other study(ies) available for bezafibrate and Liver Steatosis
| Article | Year |
|---|---|
Effects of antihypertensive and triglyceride lowering agents on splenocyte apoptosis in rats with fatty liver.
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Bezafibrate; Blood Pressure; Captopril; Caspase 3; Fatty Liver; Hypolipidemic Agents; Lipids; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Spleen; Triglycerides | 2013 |
Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective.
Topics: Animals; Bezafibrate; Disease Models, Animal; Fatty Liver; Fructose; Gene Expression; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones | 2013 |
Peroxisome proliferator-activated receptors-alpha and gamma are targets to treat offspring from maternal diet-induced obesity in mice.
Topics: Adipocytes; Adipose Tissue, White; Animals; Bezafibrate; Body Weight; Carbohydrate Metabolism; Cell Size; Diet, High-Fat; Drug Evaluation, Preclinical; Energy Intake; Energy Metabolism; Fatty Liver; Female; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR alpha; PPAR gamma; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Prenatal Nutritional Physiological Phenomena; Sterol Regulatory Element Binding Protein 1 | 2013 |
Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis.
Topics: Animals; Bezafibrate; Cell Line, Tumor; Fatty Liver; Hepacivirus; Hepatitis C; Homeostasis; Humans; Lipid Metabolism; Liver; Mice; Mice, SCID; MicroRNAs; PPAR alpha; Up-Regulation | 2014 |
Fibrates reduce triacylglycerol content by upregulating adipose triglyceride lipase in the liver of rats.
Topics: Animals; Bezafibrate; Clofibric Acid; Fatty Liver; Fenofibrate; Lipase; Lipid Peroxidation; Liver; Male; Molecular Targeted Therapy; PPAR alpha; Rats; Rats, Wistar; Triglycerides; Up-Regulation | 2013 |
Effects of antihypertensive and triglyceride-lowering agents on hepatic copper concentrations in rats with fatty liver disease.
Topics: Animals; Antihypertensive Agents; Bezafibrate; Captopril; Copper; Disease Models, Animal; Fatty Liver; Hypolipidemic Agents; Liver; Male; Metallothionein; Rats, Sprague-Dawley; Superoxide Dismutase | 2014 |
Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Fatty Liver; Glucose; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Peroxisome Proliferator-Activated Receptors | 2017 |
Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
Topics: Adipose Tissue; Animals; Bezafibrate; Diabetes Mellitus; Disease Models, Animal; Eating; Fatty Liver; Gene Expression Regulation; Glucose Tolerance Test; Glycosuria; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Metabolic Syndrome; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; RNA, Messenger; Sodium Glutamate | 2011 |
Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet.
Topics: Alanine Transaminase; Animals; Bezafibrate; Calcium Channel Blockers; Choline Deficiency; Diet; Disease Models, Animal; Fatty Liver; Hypolipidemic Agents; Liver; Liver Cirrhosis, Experimental; Male; Methionine; Nifedipine; Non-alcoholic Fatty Liver Disease; PPAR gamma; Rats; Rats, Wistar | 2012 |
[Systemic lupus erythematosus with steroid induced non-alcoholic steatohepatitis: a case report].
Topics: alpha-Tocopherol; Antioxidants; Bezafibrate; Caloric Restriction; Diet, Reducing; Fatty Liver; Female; Humans; Inclusion Bodies; Lupus Erythematosus, Systemic; Middle Aged; Neutrophil Infiltration; Prednisolone; Treatment Outcome | 2003 |
Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Blood Pressure; Captopril; Diet; Fatty Liver; Fructose; Hypolipidemic Agents; Iron; Liver; Male; Rats; Rats, Sprague-Dawley; Triglycerides | 2005 |
Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist.
Topics: Antineoplastic Agents, Hormonal; Bezafibrate; Breast Neoplasms; Diabetes Complications; Disease Progression; Fatty Liver; Humans; Hypolipidemic Agents; Prognosis; Tamoxifen; Time Factors | 2006 |
Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.
Topics: Acyl-CoA Oxidase; Alanine Transaminase; Animals; Bezafibrate; Carnitine O-Palmitoyltransferase; Cholesterol, HDL; Choline; Diet; Dose-Response Relationship, Drug; Fatty Acid-Binding Proteins; Fatty Liver; Gene Expression; Interleukin-6; Liver; Male; Methionine; Mice; Mice, Inbred C57BL; Peroxisome Proliferator-Activated Receptors; PPAR delta; RNA, Messenger; Thiazoles; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta; Transforming Growth Factor beta1; Triglycerides | 2006 |
Saying "Yes" to obese living liver donors: short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation.
Topics: Bezafibrate; Exercise Therapy; Fatty Liver; Humans; Hypolipidemic Agents; Liver Transplantation; Living Donors; Obesity | 2006 |
Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Captopril; Fatty Liver; Fructose; Hypolipidemic Agents; Male; Metabolic Syndrome; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2008 |
Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis.
Topics: Antineoplastic Agents, Hormonal; Bezafibrate; Breast Neoplasms; Chemotherapy, Adjuvant; Fatty Liver; Female; Humans; Hypolipidemic Agents; Liver Cirrhosis; Tamoxifen | 1999 |
Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
Topics: Alanine Transaminase; Alcohol Drinking; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bezafibrate; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Cholesterol; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Estrogen Receptor Modulators; Fatty Liver; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Radiotherapy, Adjuvant; Tamoxifen; Tomography, X-Ray Computed; Toremifene | 2000 |
Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen.
Topics: Adult; Antineoplastic Agents, Hormonal; Bezafibrate; Breast Neoplasms; Chemical and Drug Induced Liver Injury, Chronic; Estradiol; Fatty Liver; Female; Humans; Hypolipidemic Agents; Tamoxifen; Tomography, X-Ray Computed | 2002 |